GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Bioporto AS (OCSE:BIOPOR) » Definitions » EBIT

Bioporto AS (OCSE:BIOPOR) EBIT : kr-65.49 Mil (TTM As of Sep. 2024)


View and export this data going back to 1993. Start your Free Trial

What is Bioporto AS EBIT?

Bioporto AS's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was kr-21.29 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was kr-65.49 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Bioporto AS's annualized ROC % for the quarter that ended in Sep. 2024 was -295.11%. Bioporto AS's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -3,234.95%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Bioporto AS's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -9.80%.


Bioporto AS EBIT Historical Data

The historical data trend for Bioporto AS's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioporto AS EBIT Chart

Bioporto AS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -73.92 -66.05 -62.93 -80.46 -60.64

Bioporto AS Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.54 -12.34 -14.42 -17.44 -21.29

Competitive Comparison of Bioporto AS's EBIT

For the Diagnostics & Research subindustry, Bioporto AS's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bioporto AS's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Bioporto AS's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Bioporto AS's EV-to-EBIT falls into.



Bioporto AS EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-65.49 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bioporto AS  (OCSE:BIOPOR) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Bioporto AS's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=-86.408 * ( 1 - 6.42% )/( (25.202 + 29.599)/ 2 )
=-80.8606064/27.4005
=-295.11 %

where

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Bioporto AS's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Sep. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-85.144/( ( (1.097 + max(-2.767, 0)) + (0.551 + max(3.616, 0)) )/ 2 )
=-85.144/( ( 1.097 + 4.167 )/ 2 )
=-85.144/2.632
=-3,234.95 %

where Working Capital is:

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(4.479 + 4.294 + 9.456) - (5.625 + 0 + 15.371)
=-2.767

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(6.184 + 4.718 + 10.442) - (2.957 + 0 + 14.771)
=3.616

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Bioporto AS's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2024 )
=-65.485/668.153
=-9.80 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bioporto AS EBIT Related Terms

Thank you for viewing the detailed overview of Bioporto AS's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Bioporto AS Business Description

Traded in Other Exchanges
Address
Tuborg Havnevej 15, Ground Floor, Hellerup, DNK, DK-2900
Bioporto AS is an in-vitro diagnostic company. The company provides healthcare professionals in clinical and research settings with a range of diagnostic tests and antibodies. Its product portfolio consists of specialized monoclonal antibodies and antibody-based diagnostic assays, used in the treatment of critically ill patients. The company's products include the NGAL Test, ELISA kits, Antibodies, and Other products and licenses. Geographically, it derives a majority of its revenue from North America.

Bioporto AS Headlines

No Headlines